Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Automated parallel capillary electrophoresis system simplifies protein analysis
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Subscribe To Our Newsletter & Stay Updated